Holen Sie sich die Stockscreener-App
12.29
0.16%
0.02
Schlusskurs vom Vortag:
$12.27
Offen:
$12.38
24-Stunden-Volumen:
225.16K
Relative Volume:
0.48
Marktkapitalisierung:
$802.06M
Einnahmen:
$512.35M
Nettoeinkommen (Verlust:
$-156.23M
KGV:
-2.6834
EPS:
-4.58
Netto-Cashflow:
$7.98M
1W Leistung:
+7.71%
1M Leistung:
-6.96%
6M Leistung:
+92.94%
1J Leistung:
+204.96%
1-Tages-Spanne:
$12.04
$12.61
1-Wochen-Bereich:
$11.17
$12.61
52-Wochen-Spanne:
$3.7987
$14.38
Bioventus Inc Stock (BVS) Company Profile
Firmenname
Bioventus Inc
Sektor
Branche
Telefon
(919) 474-6700
Adresse
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Vergleichen Sie BVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
12.29 | 802.06M | 512.35M | -156.23M | 7.98M | -4.58 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-07 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Hochstufung | Craig Hallum | Hold → Buy |
| 2022-11-22 | Herabstufung | Craig Hallum | Buy → Hold |
| 2022-11-09 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Eingeleitet | Craig Hallum | Buy |
| 2021-11-15 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-11-10 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-01 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Bioventus Inc Aktie (BVS) Neueste Nachrichten
Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034 - GlobeNewswire Inc.
Connor Clark & Lunn Investment Management Ltd. Buys Shares of 258,756 Bioventus Inc. (NYSE:BVS) - MarketBeat
Segall Bryant & Hamill LLC Invests $4.52 Million in Bioventus Inc. (NYSE:BVS) - MarketBeat
Bioventus (BVS) Matches Q3 Earnings Estimates - MSN
Bioventus Inc (BVS) Shares Up 3.11% on Nov 19 - GuruFocus.com
Joint Pain Injection Market Size, Share, Trends, - openPR
Royce & Associates LP Invests $8.34 Million in Bioventus Inc. (NYSE:BVS) - MarketBeat
Los Angeles Capital Management LLC Acquires Shares of 143,464 Bioventus Inc. (NYSE:BVS) - MarketBeat
Bioventus Inc (BVS) Stock Price Down 2.45% on Nov 12 - GuruFocus.com
Bioventus Inc. (NASDAQ:BVS) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Bioventus reports robust Q3 growth, raises full-year guidance - Investing.com India
Bioventus stock target upgraded, hold buy on strong Q3 performance - Investing.com
Where are the Opportunities in (BVS) - Stock Traders Daily
Bioventus stock target upgraded, hold buy on strong Q3 performance By Investing.com - Investing.com UK
Bioventus Inc (BVS) Q3 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
Bioventus Inc (BVS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance ... - Yahoo Finance
Bioventus Reports Strong Revenue Growth in Q3 2024 - TipRanks
Bioventus (NYSE:BVS) Shares Gap DownShould You Sell? - MarketBeat
How Are Things Looking For Bioventus Inc (NASDAQ: BVS) For The Short Term? - Stocks Register
U.S. Stock market: Verrica Pharmaceuticals and Marqeta stocks plummet over 37%, while Avalon GloboCare soars 75% in volatile market trend - Business Upturn
Bioventus Inc. Revises Earnings Guidance for the Twelve Months Ending December 31, 2024 - Marketscreener.com
BVSBioventus Inc. Latest Stock News & Market Updates - StockTitan
Bioventus: Q3 Earnings Snapshot - San Francisco Chronicle
Bioventus Inc Reports Q3 2024 Earnings: Revenue Hits $139 Millio - GuruFocus.com
Bioventus (NYSE:BVS) Releases FY24 Earnings Guidance - MarketBeat
Bioventus Reports Third Quarter Financial Results - The Manila Times
Bioventus reports Q3 adjusted EPS 6c, consensus 3c - TipRanks
Viscosupplementation Market Report Analysis, Growth - openPR
Are Medical Stocks Lagging Bioventus (BVS) This Year? - Yahoo Finance
Bioventus Inc (BVS) Q3 2024 Earnings Report Preview: What To Loo - GuruFocus.com
Bioventus Inc (BVS) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Bioventus stock soars to 52-week high, hits $13.65 - Investing.com India
Bioventus stock soars to 52-week high, hits $13.65 By Investing.com - Investing.com South Africa
Bioventus (BVS) Scheduled to Post Quarterly Earnings on Tuesday - MarketBeat
Should Bioventus Stock Be in Your Portfolio Pre-Q3 Earnings? - MSN
Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024 - The Manila Times
Long Term Trading Analysis for (BVS) - Stock Traders Daily
Bioventus Surges 73% in Three Months: Time to Buy the Stock? - MSN
Bioventus (NYSE:BVS) Reaches New 1-Year HighStill a Buy? - MarketBeat
Bioventus stock soars to 52-week high, hits $13.14 - Investing.com India
SG Americas Securities LLC Lowers Stock Position in Bioventus Inc. (NYSE:BVS) - Defense World
Are Medical Stocks Lagging ChromaDex (CDXC) This Year? - Yahoo Finance
Bioventus stock soars to 52-week high of $12.43 amid growth By Investing.com - Investing.com South Africa
Bioventus (NYSE:BVS) Reaches New 52-Week HighStill a Buy? - MarketBeat
Bioventus stock soars to 52-week high of $12.43 amid growth - Investing.com Australia
Finanzdaten der Bioventus Inc-Aktie (BVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):